Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TYK2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TYK2 Pseudokinase (JH2) Domain / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View TYK2 Products |
| Gene Delivery | TYK2 Promise-ORF Full-length ORF for stable cell line construction and reporter assays. |
View TYK2 Products |
| Benchmark Ab | Anti-TYK2 Antibody Recombinant positive control for western blot and target engagement. |
View TYK2 Products |
| Validator | TYK2 siRNA Set For knockdown verification and pathway validation. |
View TYK2 Products |
| Related Target A | JAK1 Crucial for selectivity profiling and counter-screening against pan-JAK activity. |
View JAK1 Products |
| Related Target B | IL-23R Upstream receptor mediating TYK2-dependent inflammatory signaling pathways. |
View IL-23R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling across JAK family (JAK1/2/3) | Homolog panel proteins (JH1/JH2 domains) strictly verified by mass spec and theoretical MW. |
| Allosteric inhibitor binding validation | Isolated TYK2 JH2 pseudokinase domain available with >95% purity for precise SPR/TR-FRET assays. |
| Lack of reliable target controls | Sequence Verified recombinant proteins and benchmark antibodies included for baseline accuracy. |
| False Positives in cellular assays | Endotoxin Controlled (<1EU/ug) reagents and validated siRNA sets for specificity checks. |
Live TYK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TYK2 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum JAK inhibitors to highly selective allosteric small molecules targeting the JH2 pseudokinase domain. As first-generation therapies reach the clinic and achieve approval for plaque psoriasis, the next wave of R&D is targeting broader autoimmune indications such as systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), and psoriatic arthritis. Future development is heavily concentrated on optimizing oral bioavailability, extending the safety profile to completely decouple efficacy from pan-JAK toxicity, and exploring targeted protein degradation (PROTACs).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Bristol Myers Squibb, Takeda, Alumis, Ventyx | Psoriasis, SLE, IBD | Selectivity Assay (Need isolated JH2 vs JH1 mutant proteins) |
| PROTAC / Degrader | Kymera Therapeutics, BioTheryX | Refractory Autoimmune, Oncology | Ternary Complex Validation (Need High-purity Recombinant Proteins) |
| Small Molecule (Orthosteric) | Sareum, Galapagos | Psoriatic Arthritis, Solid Tumors | Kinase Activity Screening (Sequence Verified active domains) |